Trials / Completed
CompletedNCT04249505
Refractive Accuracy of "2WIN" and Portable Autorefractors
The Refractive Accuracy of Photoscreeners "2WIN" and "PlusoptiX" and the "Retinomax" Auto Refractor
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 708 (actual)
- Sponsor
- Alaska Blind Child Discovery · Academic / Other
- Sex
- All
- Age
- 6 Months – 95 Years
- Healthy volunteers
- Accepted
Summary
Youth and some adults have photoscreening refractions and hand-held auto refraction before cycloplegia refraction during new and follow up eye examinations. Vector math is applied to each refraction to determine how closely the hand-held "dry" devices match actual refraction.
Detailed description
A closeness-of-fit algorithm utilizing vector transformations of astigmatism is designed and applied to 50-years of clinical international refractive experience. As a part of new and follow up comprehensive eye examinations, patients and parents consented to confirm the cycloplegic refraction to other portable refractive tools. The ability of photoscreeners "2WIN" ("Adaptica," Padova italy), "PlusoptiX A12" (Nuremberg, Germany) and "Retinomax" (Righton, Tokyo, Japan) to match actual refraction is assessed utilizing the new algorithm. This algorithm could then be applied to batches of donated spectacles distend by charitable organizations worldwide if portable auto refracting devices are employed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | "2WIN" Photoscreener | non-cycloplegia refraction by Adaptica "2WIN" |
| DEVICE | "Plusoptix A12" | non-cycloplegic refraction by "Plusoptix A12" photoscreener |
| DEVICE | "Retinomax" | non-cycloplegic refraction by "Retinomax K+" auto refractor |
Timeline
- Start date
- 2020-01-09
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
- First posted
- 2020-01-31
- Last updated
- 2021-07-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04249505. Inclusion in this directory is not an endorsement.